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Malignant hyperthermia (MH) susceptibility is a rare life-threatening disorder that occurs upon exposure to a triggering agent. MH is
commonly due to protein-altering variants in RYR1 and CACNA1S. The American College of Medical Genetics and Genomics
recommends that when pathogenic and likely pathogenic variants in RYR1 and CACNA1S are incidentally found, they should be
reported to the carriers. The detection of actionable variants allows the avoidance of exposure to triggering agents during
anesthesia. First, we report a 10-year-old Icelandic proband with a suspected MH event, harboring a heterozygous missense variant
NM_000540.2:c.6710G>A r.(6710g>a) p.(Cys2237Tyr) in the RYR1 gene that is likely pathogenic. The variant is private to four
individuals within a three-generation family and absent from 62,240 whole-genome sequenced (WGS) Icelanders. Haplotype
sharing and WGS revealed that the variant occurred as a somatic mosaicism also present in germline of the proband’s paternal
grandmother. Second, using a set of 62,240 Icelanders with WGS, we assessed the carrier frequency of actionable pathogenic and
likely pathogenic variants in RYR1 and CACNA1S. We observed 13 actionable variants in RYR1, based on ClinVar classifications,
carried by 43 Icelanders, and no actionable variant in CACNA1S. One in 1450 Icelanders carries an actionable variant for MH.
Extensive sequencing allows for better classification and precise dating of variants, and WGS of a large fraction of the population
has led to incidental findings of actionable MH genotypes.
European Journal of Human Genetics; https://doi.org/10.1038/s41431-021-00954-2
INTRODUCTION
Malignant hyperthermia (MH) is a rare life-threatening pharmaco-
genetic disorder with the susceptibility inherited in an autosomal
dominant pattern, but the disorder only happens upon exposure
to a triggering agent (volatile anesthetics and succinylcholine).
The “gold standard” for diagnosis of MH has been in vitro
contracture test of muscle fibers in the presence of caffeine and
halothane [1]. However, this test requires a surgical biopsy and is
relatively complex to perform, so the conduct of these tests has
been centralized to highly specialized laboratories. Currently,
genetic testing may also be conducted to confirm diagnosis of MH
susceptibility [2]. MH is most commonly due to protein-altering
variants in the ryanodine receptor 1 (RYR1) gene, and less
frequently in a gene producing calcium channel alpha-1s subunit
(CACNA1S) [3]. Numerous sequence variants within those genes
and others with a potential association with MH have been
described, many of unknown significance. It is challenging to rule
out MH susceptibility in individuals with pathogenic RYR1 variants
considering the incomplete penetrance of MH susceptibility, and
individuals do not always exhibit symptoms following initial
exposure to triggering agents. The revised European Malignant
Hyperthermia Group guidelines recommend that an individual
carrying a potentially MH-associated variant should be considered
at risk of MH until contracture testing can be performed [2, 4].
Furthermore, RYR1 and CACNA1S are listed among the 59 genes
with recommendations to report incidental findings of medically
actionable variants by the American College of Medical Genetics
and Genomics (ACMG) [5]. In the last decade, the cost of whole-
exome sequencing and whole-genome sequencing (WGS) has
decreased allowing clinical application more feasible [6]. We and
others have sequenced whole genomes or whole exomes of a
large set of individuals to perform genetic studies of common and
rare diseases [7–10]. These large-scale sequence datasets can be
used as a reference of variant frequency in the context of clinical
sequencing [11], but can also lead to incidental findings.
First, we describe a case of MH in an Icelander with unknown
family history where a family-specific variant in RYR1 was
identified. We underline the value of extensive knowledge of
sequence diversity in a population to precisely determine the age
and frequency of the variant. Second, we take advantage of the
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WGS set of 62 thousand Icelanders, followed by imputation into a
total of 166 thousand Icelanders (chip-genotyped and/or whole-
genome sequenced individuals), to determine the carrier
frequency of actionable pathogenic and likely pathogenic variants
in RYR1 and CACNA1S, according to current guidelines [12]. The
detection of actionable variants causing MH susceptibility has the
potential to alter the clinical management of patients harboring




Our whole-genome sequence dataset is a collection of DNA samples from
62,240 Icelanders who have participated in various disease projects at
deCODE genetics. All participating individuals who donated blood or
buccal samples signed informed consent. The identities of participants
were encrypted using a third-party system approved and monitored by the
Icelandic Data Protection Authority.
The methods used for WGS were as follows: paired-end libraries for
sequencing were prepared from DNA samples (derived from blood or
buccal swabs) using Illumina preparation kits (TruSeq DNA, TruSeq Nano,
or TruSeq PCR-Free) according to the manufacturer’s instructions. Paired-
end sequencing-by-synthesis was performed on Illumina sequencers
(GAIIx, HiSeq 2000/2500, HiSeq X, or NovaSeq) to a target depth of 30×.
Read lengths varied from 2 × 76 to 2 × 150 bp, depending on the
instrument and/or sequencing kit used. Reads were aligned to the human
genome assembly GRCh38 using the Burrows–Wheeler Aligner version
0.7.10 [13]. Alignments were merged into a single BAM file and marked for
duplicates using Picard 1.117. Only non-duplicate reads were used for the
downstream analyses.
Variant calling and annotation
Variants were called using version 2014.4-2-g9ad6aa8 of the Genome
Analysis Toolkit (GATK) [14], reads were called with GATK using a multi-
sample configuration. The effects of sequence variants were annotated
using release 80 of the Variant Effect Predictor (VEP-Ensembl) [15]. To be
able to filter out genotypes over a certain frequency threshold we used
allelic frequencies from phased genotypes of 32.5 million SNPs and INDELs
from 28,075 Icelanders who have been whole-genome sequenced at
deCODE genetics [10]. The p.(Cys2237Tyr) variant identified in the proband
has been submitted to ClinVar (accession ID: SCV001623063). Other
variants identified in this study have been deposited to the European
Variation Archive (Project: PRJEB46486).
Sanger sequencing
Internal Sanger sequencing was performed using BigDye® Terminator
chemistry on a 3730 system (Applied Biosystems, Thermo Fisher Scientific),
with primers designed using the Primer 3 software.
Haplotype sharing
Haplotype sharing was based on long-range phased genotypes in
combination with Icelandic genealogy that allowed for parental origin of
the alleles of interest to be determined [16, 17]. When dating the
p.(Cys2237Tyr) variant in RYR1, we used these long-range haplotypes by
identifying genotype discordance between relatives of the family of the
proband.
Further details on our approach to WGS, genotyping, long-range
phasing, and imputation have been described in previous publications
[10, 18].
Case description
A 10-year-old Icelandic boy, weighing 30 kg, was admitted for appendect-
omy. He had a previous history of an uneventful volatile anesthesia for
tonsillectomy 5 years earlier. General anesthesia was induced with fentanyl
and propofol, followed by succinylcholine and maintained with sevoflurane.
A tracheal intubation was performed without complications although jaw
muscle rigidity was noted. Following induction, a fever of 39.1 °C was
detected in addition to hypercapnia with a peak pCO2 value of 80mmHg
(10.7 kPa) despite a minute ventilation of 267mL/kg/min. A venous blood gas
demonstrated a marked acidosis (pH 7.05), primarily due to respiratory
acidosis (pCO2 89mmHg (11.9 kPa)) and lactic acidosis (Lactate: 4.40mmol/L).
A clinical diagnosis of MH was made. Maintenance anesthesia was switched
to propofol infusion. The circuit filter and CO2 absorber were replaced and
2.5mg/kg of dantrolene sodium was administered with reversal of
symptoms. After completion of surgery, he was transferred to the intensive
care unit (ICU) where he got supportive care and received additional
dantrolene sodium for 24 h. Further laboratory testing demonstrated a
profound increase in creatine kinase (115.1 μg/L, normal values: <7 μg/L) and
myoglobin (41,615 μg/L, normal values: <76 μg/L) that normalized in a week.
He was extubated the following day and discharged from the hospital on
postoperative day 2 with full recovery. The proband had no overt signs of an
overwhelming sepsis, he was afebrile and hemodynamically stable on
presentation to both emergency room and operating theater, and had a
normal white blood cell count and C-reactive protein. The parents of the
proband provided consent for the publication.
RESULTS
Genetic analysis
DNA was extracted from peripheral blood from the proband with a
diagnosis of MH (IV-4 in Fig. 1) and WGS was performed. This analysis
yielded an ultra-rare, heterozygous missense variant in exon 41 of the
RYR1 gene (NM_000540.2:c.6710G>A p.(Cys2237Tyr); chr19:38,496,455
[hg38]). The majority of variants linked to MH in RYR1 are clustered in
three distinct regions (MH domain 1, 2, and 3) [19]. The p.(Cys2237Tyr)
variant identified in the proband and his relatives is located within
MH domain 2 that spans residues 2162–2458. The variant was
detected in the proband and one additional first-degree relative out
of 62 thousand WGS Icelanders. In the proband, we observed
18 sequencing reads for the reference allele and 19 reads for the
alternative allele, resulting in a variant allelic ratio of 0.51. This
genotype was confirmed with Sanger sequencing (Fig. 2D).
Determining the age and origin of p.(Cys2237Tyr)
Sanger sequencing samples from 14 close relatives of the proband
uncovered the p.(Cys2237Tyr) variant in three additional family
members (Figs. 1 and 2A–C). Samples from 14 close relatives of
the proband were Sanger sequenced (Fig. 1). This uncovered the
p.(Cys2237Tyr) variant in three additional family members
(Fig. 2A–C). The variant is present in the proband’s father (III-5),
paternal half-sibling (IV-1), and paternal grandmother (II-5).
Neither the proband’s father (III-5) nor half-sibling (IV-1) had
undergone general anesthesia, and no history of a potential
anesthetic reaction in the paternal grandmother (II-5) was
available.
The paternal grandmother (II-5) harbors the variant with a low
allelic ratio on WGS, 0.21 (6 out of 28 WGS reads), and 0.20 allelic
ratio on Sanger sequencing (Fig. 2A). This is consistent with
mosaicism in the paternal grandmother of the proband (II-5), as
the allelic ratio deviates from the expected heterozygous allelic
balance of 50/50 (p value= 0.0015). However, in the three
descendants of the paternal grandmother (II-5) carrying the
variant (III-5, II-1, and IV-4 the proband), the allelic ratio does not
deviate from the expected allelic balance of 50/50 ratio. This
suggests that the variant was transmitted from the paternal
grandmother (II-5) to her descendants and is present in mosaic
form in her somatic and germline cells. Using haplotype sharing
based on phased and parent-of-origin determined chip-genotypes
(Illumina array) and WGS data, we found that all four confirmed
carriers share a haplotype background (genomic coordinate
chr19:3,890,643-53,628,382 [hg38]) containing the p.(Cys2237Tyr)
variant. The haplotype containing the variant was traced to a
maternally inherited haplotype in the proband’s paternal grand-
mother (II-5). The same haplotype is also observed in her younger
sister (II-2), who is not a carrier of the p.(Cys2237Tyr) variant. Taken
together, the allelic imbalance in the paternal grandmother of the
proband (II-5) and the absence of the identified variant in her
sister (II-2), despite a shared maternal haplotype encompassing
RYR1, is consistent with an early de novo mutation in the II-5.
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Fig. 2 The Sanger sequencing chromatogram of the p.(Cys2237Tyr) variant at chr19:38,496,455 [hg38] in RYR1 in all four carriers
(highlighted with a red box). The reference allele is indicated with a blue peak and the alternative allele is indicated with a red peak. The
variant is present in a heterozygous state in the proband (D), his paternal half-brother (C), and his father (B). The paternal grandmother (A)
carries the variant in low allelic ratio, consistent with mosaicism, with ~0.20 allelic ratio.
Fig. 1 The pedigree of the proband (IV-4). HT corresponds to haplotype sharing of individuals encompassing the genomic coordinate of the
variant in RYR1 (chr19:38,496,455 [hg38]). [−/+] refers to confirmed carriers of the genotype, and [−/−] refers to non-carriers, confirmed by
Sanger sequencing. Individual II-2 does not carry the variant; however, she shares the same haplotype background as individual II-5
(a confirmed carrier of the variant with 22 reads for reference allele and 6 for alternative allele). This implies that p.(Cys2237Tyr) led to
mosaicism that occurred in the paternal grandmother (II-5) of proband. The years of birth and death of family members in generation I and II
are 5-year rounded.
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Overall, the p.(Cys2237Tyr) variant is found in four individuals
within three generations in the proband’s family (Fig. 1). No
additional carriers of this variant were found in WGS data from
over 62 thousand Icelandic individuals (a population of 360
thousand) or in WGS data from 30 thousand foreign individuals
(mainly from European countries) sequenced at deCODE genetics.
This suggests that the p.(Cys2237Tyr) variant observed in Iceland
is a de novo mutation that took place in the paternal grandmother
when she was an early embryo in a cell with descendants that
contributed to both somatic and germ cells. The p.(Cys2237Tyr)
variant has been reported before outside of Iceland in a single MH
family in the Netherlands. Diagnosis of the index patient of that
family was confirmed with a positive in vitro contracture test [1].
Actionable MH variants in the Icelandic population
The ACMG guidelines recommend reporting of incidental findings
in RYR1 and CACNA1S of previously classified pathogenic and likely
pathogenic variants in the context of MH [5]. By October 2020, a
total of 2728 coding or splice site variants in RYR1 are represented
in ClinVar of which 367 are considered to be actionable since they
are classified as pathogenic and/or likely pathogenic, after
excluding variants with conflicting interpretation. The annotation
in ClinVar database is not specific for a given phenotype; however,
individuals with pathogenic or likely pathogenic variants linked to
RYR1-associated myopathies are reported to be at risk for MH
during general anesthesia and should avoid triggering anesthetics
[4, 20]. In a set of 62 thousand WGS Icelanders, we detected 369
coding or splice variants in RYR1 with minor allele frequency (MAF)
<0.1% (Supplementary Table 1). Out of these 369 variants (MAF <
0.1%), we observed 13 actionable variants carried by 43 out of 62
thousand WGS Icelanders. This corresponds to a carrier frequency
of 1 in 1450 of actionable RYR1 variant, or 0.069% (out of all WGS
Icelanders). Through imputation (166K chip-genotyped Icelanders)
and Sanger sequencing of relatives, we identified 39 additional
carriers of actionable RYR1 variants, bringing the total to 82
carriers. This results in 1 in every 2000 individuals (chip-genotyped
Icelanders) carrying a known pathogenic variant in RYR1 (Tables 1
and 2). For CACNA1S, a total of 764 coding or splice site variants
are represented in ClinVar, of which 36 variants are considered to
be actionable. We detected 125 coding or splice site variants in
CACNA1S with MAF < 0.1% out of 62K WGS Icelanders (Supple-
mentary Table 2), but none are actionable (Table 1).
DISCUSSION
First, we present a case of MH in a 10-year-old boy harboring a
family-specific variant in RYR1, p.(Cys2237Tyr), which is classified
as likely pathogenic. Second, we estimate overall carrier frequency
of actionable variants in RYR1 and CACNA1S among 62K WGS
Icelanders, finding that 1 in every 1450 WGS Icelanders carries an
actionable RYR1 variant and none carry actionable CACNA1S
variants.
The presentation of MH in the proband, a 10-year-old boy
receiving an inhaled anesthetic who additionally received
succinylcholine, was classic. It should be noted that while
additional dantrolene was given in the ICU, it is not required
after normalization of PaCO2 and with a decreased core
temperature, although monitoring is required [21]. When the
clinical status of the proband was applied to the clinical grading
scale to predict MH susceptibility, the proband received a score of
70 pts (15 pts each for masseter spasm, CK elevation, respiratory
acidosis, inappropriate temperature increase, and 10 pts for
acidosis), rendering the likelihood of an MH episode as almost
certain [22]. According to the European Malignant Hyperthermia
Group, the suggested diagnostic pathway for patients with MH
suspicion includes either genetic testing or in vitro contracture
testing [2], which has largely been centralized to increase
diagnostic accuracy. A genetic workup was performed identifying
a RYR1 variant (p.(Cys2237Tyr), chr19:38,496,455 [hg38]). The
p.(Cys2237Tyr) variant is rare, absent from 212 thousand
individuals in gnomAD reference database (v2.1 and v3.0) [11].
This same variant was reported positive for in vitro contracture
testing in a case [1], and pathogenic prediction tools identify a
high risk of damaging effect to the protein function [23].
Therefore, the variant classifies as likely pathogenic based on
both MHS/RYR1-specific adaptation of the ACMG criteria, and the
genetic scoring matrix from The European Malignant Hyperther-
mia group [24, 25]. This variant is currently not listed in ClinVar, a
genotype–phenotype relationship reference database. The fre-
quency of a sequence variant is a key determinant in the
classification of pathogenicity, but it can be difficult to assess
precisely. In Iceland, the extent of WGS and genotyping of 20%
and 50% of the population, respectively, allows us to precisely
determine the allelic frequency, the background haplotype, and
the generation where the mutation that led to the variant
happened. The p.(Cys2237Tyr) mutation led to mosaicism present
in both germline cells of the proband’s paternal grandmother and
her somatic cells (II-5). This variant was then inherited by three of
her descendants, including the MH proband. Previously, this
variant was reported once in a single individual outside of Iceland
with an episode of MH, indicating that the variant identified in the
Icelandic proband corresponds to a recurrent mutation. We note
that the variant is located in MH domain 2, a region enriched for
pathogenic missense variants between residues 2162 and 2458.
The genetic workup identified two other alive family members
without an anesthetic exposure who are likely to be susceptible to
MH, out of 14 tested family members [2]. Given the large size of
the RYR1 gene (5038 amino acids, and ranks 27th largest out of
19,689 genes) and multiple variants within the gene that are of
uncertain clinical significance, it is of utmost importance to
attempt a molecular diagnosis of MH cases, and to distribute
information about pathogenic variants.
Based on a large set of WGS Icelanders (n= 62 thousand), we
determined that 1 in 1450 individuals carries one of the 13
actionable variants likely to cause MH in Iceland, all within RYR1
(Table 2). After complementing WGS by imputation into a larger
set followed by Sanger sequencing, we identified a total of 82
individuals carrying actionable variants likely to cause MH
susceptibility.
In summary, this report shows how extensive knowledge
of sequence diversity is instrumental in two different contexts
for one condition. First, on an individual level, this allows
interpretation of clinical sequencing results where the extent of
the sequencing combined with the genealogy allows for precise
Table 1. Coding and splice variants (MAF < 0.1%) in RYR1 and CACNA1S detected in the Icelandic population.
Gene Carriers of any variant out of 62K WGS
(no. of variants)
Carriers of P/LP variants out of 62K WGS
(no. of variants)
Imputeda carriers of P/LP variants out of
166K (no. of variants)
RYR1 2751 (369) 43 (13) 82 (13)
CACNA1S 799 (125) 0 (0) 0 (0)
P/LP pathogenic and likely pathogenic variants on ClinVar.
aChip-genotyped and/or whole-genome sequenced individuals.
R. Fridriksdottir et al.
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dating of variants and assessing their pathogenicity. Second,
at a population level, the detection of actionable variants in a
large dataset has the potential to assist in the delivery of
healthcare.
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